Antihypertensive Effects and Safety of Isradipine in Patients with Essential Hypertension

摘要

Background Antihypertensive treatment represents the modification of one of the most important risk factors on the development of cardiovascular, cerebrovascular and peripheral vascular disease. In cases of markedly developed atherosclerosis, reduction of blood pressure can improve the survival of patients by reducing the incidence and/or severity cerebrovascular events. We studied a new dihydropyridine calcium antagonist isradipine to evaluate the efficacy and safety in patients with essential hypertension. Method After a placebo run-in phase of four weeks duration, 2.5mg isradipine once daily orally was administered for four weeks to 84 patients (48 males, 36 females ; mean age ; 50.8 years). And then 5.0mg isradipine once daily was administered for four weeks to 59 patients whose diastolic pressure did not decrease less than 90 mmHg. Results 1) At the end of 8 weeks of therapy, systolic and diastolic blood pressure were significantly reduced from 158.2±11.5/101.7±5.1mmHg in sitting, 156.8±13.7/102.3±5.6mmHg in standing to 138.3±13.8/90.1±6.7mmHg in sitting, 137.6±13.7/91.2±7.6mmHg in standing (p Conclusion These results indicate that isradipine is effective and safe antihypertensive agent in the treatment of essential hypertension.